Acutarial..Sadly your analysis tracks the analysis of my friend who researches biotech opportunities. I asked him to take a look here and he concluded that the studies are showing only moderate effectiveness. He didn't think any major pharma would make a big investment here based on current results. I still wonder how many of these subjects have been exposed to previous modern medicine treatments that have devastated their immune systems. I think a study would only be valid if Pela was used as part of a first line treatment. I still think the valuation is low based on other pharma buyouts in the area....but the I don't think the fantastical predictions of our friend KWSdeluxe are gonna come true any time soon.